Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19705365 | 1.00 | EPHX2 (0.40) | EPHX2GBA1ALDH1A1TDP1HCRTR2 | |
| SCHEMBL15746435 | 0.94 | EPHX2 (0.35) | EPHX2HCRTR2 | |
| SCHEMBL26404577 | 0.89 | TSHR (0.36) | EPHX2ALDH1A1TDP1HCRTR2 | |
| SCHEMBL10327057 | 0.86 | HCRTR2 (0.36) | HCRTR2 | |
| SCHEMBL10077153 | 0.86 | HCRTR2 (0.36) | HCRTR2 | |
| SCHEMBL5987408 | 0.85 | — | — | |
| SCHEMBL11451186 | 0.83 | GBA1 (0.50) | EPHX2GBA1ALDH1A1TDP1 | |
| Ammonia Solution, Strong SCHEMBL4076473 | 0.83 | EPHX2 (0.45) | EPHX2GBA1ALDH1A1TDP1 | |
| SCHEMBL20518475 | 0.81 | GBA1 (0.39) | EPHX2GBA1ALDH1A1TDP1SPHK1 | |
| SCHEMBL28356186 | 0.81 | GBA1 (0.39) | EPHX2GBA1ALDH1A1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2022-06-16 | — | — | US | disclosed |
| US-11345698-B2 | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-05-31 | — | — | US | disclosed |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
| US-9868742-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868742-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-14 | — | — | US | disclosed |
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | EPHX2 4113/4885GBA1 1/4885ALDH1A1 2739/4885 |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | EPHX2 4113/4885GBA1 1/4885ALDH1A1 2739/4885 |
| US-11345698-B2 | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders | PARK7, GBA1, SNCA | EPHX2 4426/4885GBA1 2/4885ALDH1A1 1911/4885 |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | EPHX2 4113/4885GBA1 1/4885ALDH1A1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.